IPP Bureau
5.1 lakh TB patients notified across India
By IPP Bureau - February 23, 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
By IPP Bureau - February 22, 2025
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala
By IPP Bureau - February 22, 2025
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg
By IPP Bureau - February 22, 2025
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
Roche Diagnostics India screens 5,000 children for eye health
By IPP Bureau - February 21, 2025
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
GSK's Nucala application for COPD accepted for review in China
By IPP Bureau - February 21, 2025
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets
By IPP Bureau - February 21, 2025
Wanbury reports 88% drop in Q3 FY25 PAT
By IPP Bureau - February 21, 2025
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
By IPP Bureau - February 21, 2025
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
USFDA classifies Aurobindo Pharma Inc's warehouse as OAI
By IPP Bureau - February 21, 2025
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
By IPP Bureau - February 21, 2025
The inspection was successfully completed
European Commission approves Biocon Biologics' Ustekinumab Biosimilar
By IPP Bureau - February 21, 2025
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Lupin receives EIR from USFDA for its Somerset manufacturing facility
By IPP Bureau - February 21, 2025
the inspection conducted from January 27 to January 31, 2025
USFDA issues Form-483 for Piramal Pharma's facility at Turbhe
By IPP Bureau - February 21, 2025
Observations are largely around improvement of procedures and practices
Orchid Pharma's Alathur API facility successfully completes USFDA inspection
By IPP Bureau - February 20, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
